Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pediatric Drugs
Published in: Pediatric Drugs 5/2009

01-10-2009 | Original Research Article

Pharmacotherapy in Pediatric Critical Illness

A Prospective Observational Study

Authors: Conor McDonnell, Stanley Hum, Helena Frndova, Dr Christopher S. Parshuram

Published in: Pediatric Drugs | Issue 5/2009

Login to get access

Abstract

Background and Objectives: Pharmacotherapy is an under-evaluated element of critical care medicine. In order to better understand pharmacotherapy in pediatric critical illness, we evaluated a cohort of emergency admissions to a university-affiliated pediatric intensive care unit (PICU).
Methods: A prospective, observational study was performed. Eligible patients were admitted to this medical-surgical ICU for at least 24 hours. The primary outcomes were the number of drug orders written, the number of different medications ordered, and the number of drug administrations. Multiple regression analyses were used to identify factors independently associated with each primary outcome.
Results: We studied 100 patients with a median age of 40 months (interquartile range [IQR] 9–82), who were admitted for a total of 851 ICU days. These patients received 4419 drug orders and 11 911 intermittent dose-administrations of 241 different medications. Each patient received a median of 29.5 (IQR 16.5–48.5) drug orders, 14 (IQR 9–18.5) different medications, and 58 (IQR 28–129) drug administrations while in the ICU. The most frequent orders were for morphine 457 (10.6%), furosemide (frusemide) 337 (7.8%), potassium 237 (5.5%), lorazepam 226 (5.2%), and albuterol (salbutamol) 158 (3.7%). The duration of PICU stay and severity of illness were independently associated with all primary outcomes.
Conclusions: Pharmacotherapy is an active component in the practice of pediatric critical care medicine. We demonstrated that increasing numbers of ordered medications, drug orders, and drug administrations were associated with increasing duration of ICU therapies and the length of ICU stay. These data underscore the potential importance of improved safety and efficacy of medicines used to treat critically ill children.
Literature
1.
Tobias JD. Sedation and analgesia in the pediatric intensive care unit. Pediatr Ann 2005 Aug; 34(8): 636–45PubMed
2.
3.
Giacoia GP, Birenbaum DL, Sachs HC, et al. The newborn drug development initiative. Pediatrics 2006 Mar; 117(3 Pt 2): S1–8PubMed
4.
Esteban A, Anzueto A, Frutos F, et al. Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAMA 2002 Jan 16; 287(3): 345–55PubMedCrossRef
5.
Herridge MS, Cheung AM, Tansey CM, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 2003 Feb 20; 348(8): 683–93PubMedCrossRef
6.
Conrad SA, Rycus PT, Dalton H. Extracorporeal life support registry report 2004. ASAIO J 2005 Jan–Feb; 51(1): 4–10PubMedCrossRef
7.
de Mos N, van Litsenburg RR, McCrindle B, et al. Pediatric in-intensive-care-unit cardiac arrest: incidence, survival, and predictive factors. Crit Care Med 2006 Apr; 34(4): 1209–15PubMedCrossRef
8.
Bordun LA, Butt W. Drug errors in intensive care. J Paediatr Child Health 1992 Aug; 28(4): 309–11PubMedCrossRef
9.
Darchy B, Le Miere E, Figueredo B, et al. Iatrogenic diseases as a reason for admission to the intensive care unit: incidence, causes, and consequences. Arch Intern Med 1999 Jan 11; 159(1): 71–8PubMedCrossRef
10.
Boucher BA, Kuhl DA, Coffey BC, et al. Drug use in a trauma intensive-care unit. Am J Hosp Pharm 1990 Apr; 47(4): 805–10PubMed
11.
Buchanan N, Cane RD. Drug utilization in a general intensive care unit. Intensive Care Med 1978 Apr; 4(2): 75–7PubMedCrossRef
12.
Farina ML, Levati A, Tognoni G. A multicenter study of ICU drug utilization. Intensive Care Med 1981 Apr; 7(3): 125–31PubMedCrossRef
13.
Kaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA 2001; 285(16): 2114–20PubMedCrossRef
14.
Aranda JV, Clarkson S, Collinge JM. Changing pattern of drug utilization in a neonatal intensive care unit. Am J Perinatol 1983 Oct; 1(1): 28–30PubMed
15.
Gavrilov V, Lifshitz M, Levy J, et al. Unlicensed and off-label medication use in a general pediatrics ambulatory hospital unit in Israel. Isr Med Assoc J 2000 Aug; 2(8): 595–7PubMed
16.
Bajcetic M, Jelisavcic M, Mitrovic J, et al. Off label and unlicensed drugs use in paediatric cardiology. Eur J Clin Pharmacol 2005 Nov; 61(10): 775–9PubMedCrossRef
17.
Manor-Shulman O, Beyene J, Frndova H, et al. Quantifying the volume of documented clinical information in critical illness. J Crit Care 2008 Jun; 23(2): 245–50PubMedCrossRef
18.
Pollack MM, Patel KM, Ruttimann UE. PRISM III: an updated Pediatric Risk of Mortality score. Crit Care Med 1996 May; 24(5): 743–52PubMedCrossRef
19.
Leteurtre S, Martinot A, Duhamel A, et al. Validation of the paediatric logistic organ dysfunction (PELOD) score: prospective, observational, multicentre study. Lancet 2003 Jul 19; 362(9379): 192–7PubMedCrossRef
20.
Farias JA, Frutos F, Esteban A, et al. What is the daily practice of mechanical ventilation in pediatric intensive care units? A multicenter study. Intensive Care Med 2004 May; 30(5): 918–25PubMedCrossRef
21.
Flori HR, Glidden DV, Rutherford GW, et al. Pediatric acute lung injury: prospective evaluation of risk factors associated with mortality. Am J Respir Crit Care Med 2005 May 1; 171(9): 995–1001PubMedCrossRef
22.
Goldstein SL, Somers MJ, Baum MA, et al. Pediatric patients with multi-organ dysfunction syndrome receiving continuous renal replacement therapy. Kidney Int 2005 Feb; 67(2): 653–8PubMedCrossRef
23.
Anand KJ, Aranda JV, Berde CB, et al. Summary proceedings from the neonatal pain-control group. Pediatrics 2006 Mar; 117(3 Pt 2): S9–22PubMed
24.
Tobias JD, Rasmussen GE. Pain management and sedation in the pediatric intensive care unit. Pediatr Clin North Am 1994 Dec; 41(6): 1269–92PubMed
25.
Deshmukh CT, Rane SA, Gurav MN. Hypomagnesaemia in paediatric population in an intensive care unit. J Postgrad Med 2000 Jul–Sep; 46(3): 179–80PubMed
26.
Cook D, Crowther MA, Douketis J. Thromboprophylaxis in medical-surgical intensive care unit patients. J Crit Care 2005 Dec; 20(4): 320–3PubMedCrossRef
27.
Duncan H, Hutchison J, Parshuram CS. The pediatric early warning system score: a severity of illness score to predict urgent medical need in hospitalized children. J Crit Care 2006 Sep; 21(3): 271–8PubMedCrossRef
28.
Leteurtre S, Duhamel A, Grandbastien B, et al. Paediatric logistic organ dysfunction (PELOD) score. Lancet 2006 Mar 18; 367(9514): 897; author reply 900–2PubMedCrossRef
29.
Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med 2003 Sep 18; 349(12): 1157–67PubMedCrossRef
30.
Besunder JB, Reed MD, Blumer JL. Principles of drug biodisposition in the neonate: a critical evaluation of the pharmacokinetic-pharmacodynamic interface (part I). Clin Pharmacokinet 1988 Apr; 14(4): 189–216PubMedCrossRef
31.
Rothschild JM, Landrigan CP, Cronin JW, et al. The Critical Care Safety Study: the incidence and nature of adverse events and serious medical errors in intensive care. Crit Care Med 2005 Aug; 33(8): 1694–700PubMedCrossRef
32.
Sharek PJ, Classen D. The incidence of adverse events and medical error in pediatrics. Pediatr Clin North Am 2006 Dec; 53(6): 1067–77PubMedCrossRef
33.
Leape LL, Cullen DJ, Clapp MD, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 1999 Jul 21; 282(3): 267–70PubMedCrossRef
34.
Wilson GN, Moore KA. Multiple-order intravenous drug management system in a medical/surgical intensive care unit: opportunities and challenges for pharmacy practice. ASHP Midyear Clinical Meeting 1990; 25: 261d
35.
Parshuram CS, Ng GY, Ho TK, et al. Discrepancies between ordered and delivered concentrations of opiate infusions in critical care. Crit Care Med 2003 Oct; 31(10): 2483–7PubMedCrossRef
36.
Rothschild JM, Keohane CA, Cook EF, et al. A controlled trial of smart infusion pumps to improve medication safety in critically ill patients. Crit Care Med 2005 Mar; 33(3): 533–40PubMedCrossRef
37.
Weinger MB. Drug wastage contributes significantly to the cost of routine anesthesia care. J Clin Anesth 2001 Nov; 13(7): 491–7PubMedCrossRef
38.
Parshuram CS. Pharmacotherapeutic friendly fire in the intensive care unit: high stakes seeking high calibre. Crit Care 2008; 12(2): 137–8PubMedCrossRef
39.
Lopez Martinez R, Cabanas Poy MJ, Oliveras Arenas M, et al. Drug use in a neonatal ICU: a prospective study. Farm Hosp 2005 Jan–Feb; 29(1): 26–9PubMedCrossRef
40.
Uppal N, Dupuis L, Parshuram CS. Paediatric labelling in drug monographs contained in the Canadian Compendium of Pharmaceuticals and Specialties. Pediatr Drugs 2008 May; 10(3): 193–7CrossRef
Metadata
Title
Pharmacotherapy in Pediatric Critical Illness
A Prospective Observational Study
Authors
Conor McDonnell
Stanley Hum
Helena Frndova
Dr Christopher S. Parshuram
Publication date
01-10-2009
Publisher
Springer International Publishing
Published in
Pediatric Drugs / Issue 5/2009
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI
https://doi.org/10.2165/11310670-000000000-00000

Other articles of this Issue 5/2009

Pediatric Drugs 5/2009 Go to the issue

Review Article

Antivirals for Cytomegalovirus Infection in Neonates and Infants

Meeting Report

Pediatric Pharmacy Advocacy Group International Pediatric Pharmacy and Pharmacology Symposium, 24–26 April 2009; Orlando, Florida, USA

Adis Drug Profile

Pneumococcal Polysaccharide Protein D-Conjugate Vaccine (Synflorix™; PHiD-CV)

Therapy In Practice

Epidemiology and Management of Essential Tremor in Children